REGN Q3 2018 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.7B+10.8% YoY

Gross Profit

$1.5B91.2% margin

Operating Income

$627M37.7% margin

Net Income

$595M35.7% margin

EPS (Diluted)

$5.17

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$453M

Free Cash Flow

$347M

Stock-Based Comp.

$111M

Balance Sheet

Total Assets

$10.8B

Total Liabilities

$2.9B

Stockholders' Equity

$7.9B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.7B	$1.5B	+10.8%
Gross Profit	$1.5B	$1.4B	+11.7%
Operating Income	$627M	$560M	+12.0%
Net Income	$595M	$388M	+53.1%

Revenue Segments

Product

$1.0B100%